LLY Eli Lilly and Company Loading...

From ABBV earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
14:00
Feb 04 ◎
Rob Michael Chairman and Chief Executive Officer, AbbVie Inc. ABBV Q4 FY25 call
The IL-23 category in IBD is expanding rapidly, but Skyrizi's frontline capture rate is ~75% in IBD overall and ~80% in Crohn's, showing no impact from newer competitors. — This indicates Eli Lilly's Omvoh is largely gaining second-line share, not capturing new frontline patients, limiting its potential to displace Skyrizi in the most valuable first-line segment.
LLY
MED

About LLY Analyst Coverage

Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Rob Michael.